Supreme Court Challenges Government on Medicine Price Controls
The Supreme Court scrutinizes the government's reluctance to regulate medicine prices, questioning the impact on patients.
Supreme Court questions why many medicines are excluded from price control.
Government defends its selective approach to drug pricing amidst rising costs.
Court highlights significant price disparities affecting patient access to essential medicines.
The Supreme Court of India has raised critical questions regarding the government's approach to regulating medicine prices, particularly why a significant number of drugs remain outside the price control framework. During a hearing on October 27, 2026, the Court expressed concern that the Union government's reliance on market dynamics fails to justify the exorbitant prices patients face, which can be drastically higher than procurement costs.
Justice Sandeep Mehta emphasized the moral implications of the pricing policies, urging the government to prioritize the welfare of citizens over commercial interests. He highlighted a stark example where a chemotherapy drug was priced at ₹1.3 lakh in a hospital, while the dealer price was merely ₹11,000. This prompted the Court to demand explanations for such price gouging and the rationale behind the government's selective regulation of medicines under the Drugs (Prices Control) Order, 2013.
The Additional Solicitor General, Aishwarya Bhati, defended the government's stance, asserting that a balanced approach is necessary to foster innovation and competition within the pharmaceutical sector. She argued that imposing blanket price controls could stifle industry growth and employment opportunities. However, the Court challenged this view, questioning whether allowing manufacturers to set high maximum retail prices (MRPs) was truly beneficial for consumers.
The implications of the Court's inquiries are significant, as they highlight the ongoing struggle between ensuring affordable healthcare and maintaining a profitable pharmaceutical industry. The Court's scrutiny of the government's pricing policies could lead to broader regulatory changes, potentially reshaping how medicines are priced and accessed in India. The discussion also reflects a growing awareness of the need for transparency and fairness in drug pricing, especially for life-saving treatments.
Looking ahead, the Court has reserved its order, indicating that further developments in this case could prompt the government to reconsider its pricing strategies. Stakeholders in the healthcare sector, including hospitals and pharmaceutical companies, will be closely monitoring the situation as the Court's decision may have far-reaching consequences for drug affordability and patient access in India.
